First human trial of ETD-001 gel begins safety testing
NCT ID NCT07674862
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety and tolerability of ETD-001 gel in healthy Chinese adults aged 18 to 60. Participants receive either the gel or a placebo, with doses increased gradually. The study aims to understand how the body processes the gel and whether it causes any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ETD-001 gel
- What this could lead to
- If safe and well-tolerated, this could pave the way for future studies testing ETD-001 gel for medical conditions.
- What could go wrong
- This is an early Phase 1 trial with only 56 healthy participants, so results may not predict effectiveness or safety in patients. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hangzhou
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Decades-Old drug reverse pancreatic scarring?
- Could KP405 offer a new way to tackle Parkinson's?
- Stem cells injected into heart arteries may help repair damage after a heart attack
- New hope for transplant patients with hepatitis b: safer drug switch under study
- New vaginal ring aims to prevent HIV and pregnancy in one device
- Can training hospital staff on gun safety prevent child shootings?